TREOS’s Products

At TREOS we use our proprietary platform technology to predict human’s immune responses to a wide range of cancers and disease pathogens. We use this knowledge to create highly effective immunotherapies against different cancers and preventive vaccines against emergent viral diseases.

Peptide Cancer Vaccines

TREOS’ system has enabled us to develop two families of cost-effective, industrially scalable, rapidly delivered, off-the-shelf and personalized products without the need for tumor biopsy.

POLYPEPI Off-the-shelf Peptide Cancer Vaccines

Off-the-shelf products contain 6-12 shared tumor antigen derived peptides (PEPIs) optimized for a genetically broad population. 

Clinical trials conducted with our lead product, PolyPEPI1018, consistently confirmed exceptionally broad T cell responses against at least 3 tumor antigens in high proportion of patients, conform to model predictions.

Personalized Peptide Cancer Vaccines

PEPI Panel – A unique approach for off-the-shelf personalized cancer vaccine generation

Our Peptide Library (PEPI Panel) currently contains 3,286 proprietary, immunogenic peptide fragments from 184 tumor antigens associated with 19 cancer indications that induce immune responses in the largest subpopulation of subjects, based on HLA genotype (both class I and II) of 16,000 subjects. PEPI Panel approach guides selection of 12 individual peptides tailored to the tumor type and HLA genotype of patients from a warehouse of off-the-shelf peptides permitting the administration of personalized immunotherapy with unprecedently broad immunogenicity (Csiszovszki et al SITC 2019).

Treos’ differentiated and scalable approach provides substantial competitive advantage over all other approaches in the personalized cancer immunotherapy field, and offers an exclusive opportunity to produce personalized products faster and cheaper.

PolyPEPI Preventive Vaccines against Infectious Diseases

Using our proprietary computational vaccine design technology, we have developed a PolyPEPI preventive peptide vaccine against COVID-19 (SARS-CoV-2).

The design of PolyPEPI-SCoV-2 exploits our knowledge on genetic heterogeneity of individuals and ethnicities. PolyPEPI-SCoV-2 vaccine can elicit broad and long-lasting immune responses in vaccinated subjects and can therefore protect people against COVID-19, worldwide. PolyPEPI-SCoV-2 contains 9 different peptide fragments from the four structural protein of the virus. Mutations of the virus will not affect the global coverage of our vaccine; the majority of subjects are expected to have a broad repertoire of virus-specific memory. Preclinical results support the use of our peptide vaccine also in post-exposure prophylaxis, as alternative vaccination strategy (Somogyi et al Front. Immunol 2023).

Intellectual Property

Subject Matter and IP status

Personalized Immunogenic Peptide Identification Platform

Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

2 MAR 2018

Off-the-shelf, Population-based Immunogenic Peptide Identification Platform

Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in China, Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, Japan, South Korea, Singapore, South-Africa.

2 MAR 2018

“PEPI PANEL” Composition and Process for Selecting Peptides from PEPI PANEL Peptide Library for Off-the-shelf Personalized Cancer Treatments

Published. Pending PCT application. Regional applications filed in 50+ countries.

3 SEP 2019

“HLAT screening” Immunogenetic Cancer Screening Test Determining a Subject’s Risk of Developing Cancer

Published. Pending PCT application. Regional applications filed in 50+ countries. Allowed in Japan.

3 SEP 2019

Compositions of Colorectal-, Breast-, Ovarian cancers Off-the-shelf Peptide immunotherapies

Published. PolyPEPI1018 CRC immunotherapy granted (US PTO). Pending PCT application. Regional applications filed in 50+ countries. Allowed in USA, Colombia and Singapore.

2 MAR 2018

Compositions of Gastric-, Bladder-, Lung cancers & Melanoma Off-the-shelf Peptide Immunotherapies

Published. Pending PCT application. Regional applications filed in 50+ countries. Gastric peptide compositions allowed in USA and Saudi Arabia.

3 SEP 2019

Composition of coronavirus vaccine product

Published and allowed in USA, pending PCT application. Regional applications filed worldwide in 47 countries.

3 APR 2020

Trade Secrets: Knowledgebase of peptide targets; Algorithm; Databases

Not applicable (N/A)

N/A

Subject Matter and IP status

  • Personalized Immunogenic Peptide Identification Platform

    2 MAR 2018

    Published. Pending PCT application.
    Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

  • Off-the-shelf, Population-based Immunogenic Peptide Identification Platform

    2 MAR 2018

    Published. Pending PCT application.
    Regional applications filed in 50+ countries. Allowed in China, Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, Japan, South Korea, Singapore, South-Africa.

  • “PEPI PANEL” Composition and Process for Selecting Peptides from PEPI PANEL Peptide Library for Off-the-shelf Personalized Cancer Treatments

    3 SEP 2019

    Published. Pending PCT application. Regional applications filed in 50+ countries.

Subject Matter and IP status

  • Published. Pending PCT application.
    Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

    FILLING DATE: 2 Mar 2018

  • Published. Pending PCT application.
    Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

    FILLING DATE: 2 Mar 2018

  • Published. Pending PCT application.
    Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

    FILLING DATE: 2 Mar 2018

  • Published. Pending PCT application.
    Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

    FILLING DATE: 2 Mar 2018

  • Published. Pending PCT application.
    Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

    FILLING DATE: 2 Mar 2018

  • Published. Pending PCT application.
    Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

    FILLING DATE: 2 Mar 2018

  • Published. Pending PCT application.
    Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

    FILLING DATE: 2 Mar 2018

  • Published. Pending PCT application.
    Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

    FILLING DATE: 2 Mar 2018

Subject Matter and IP status

Personalized Immunogenic Peptide Identification Platform

Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

FILLING DATE: 2 Mar 2018

Personalized Immunogenic Peptide Identification Platform

Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

FILLING DATE: 2 Mar 2018

Personalized Immunogenic Peptide Identification Platform

Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

FILLING DATE: 2 Mar 2018

Personalized Immunogenic Peptide Identification Platform

Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

FILLING DATE: 2 Mar 2018

Personalized Immunogenic Peptide Identification Platform

Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

FILLING DATE: 2 Mar 2018

Personalized Immunogenic Peptide Identification Platform

Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

FILLING DATE: 2 Mar 2018

Personalized Immunogenic Peptide Identification Platform

Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

FILLING DATE: 2 Mar 2018

Personalized Immunogenic Peptide Identification Platform

Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.

FILLING DATE: 2 Mar 2018